Hiren V Patel1, Arnav Srivastava1, Ramaprasad Srinivasan2, Eric A Singer1. 1. Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey. 2. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: As molecular profiling of renal cell carcinoma (RCC) continues to elucidate novel targets for nonclear cell histologies, understanding the landscape of these targets is of utmost importance. In this review, we highlight the genomic landscape of nonclear cell RCC and its implications for current and future systemic therapies. RECENT FINDINGS: Several genomic studies have described the mutational burden among nonclear cell histologies. These studies have highlighted the importance of MET in papillary RCC and led to several clinical trials evaluating the efficacy of MET inhibitors for papillary RCC. The success of immune checkpoint inhibitors, such as ipilimumab and nivolumab, in clear cell RCC has led to ongoing trials evaluating these novel therapeutics in nonclear cell RCC. SUMMARY: Genomic profiling has allowed for the evaluation of novel targets for nonclear cell RCC. This evolving therapeutic landscape is being explored in promising, ongoing trials that have the potential for changing how nonclear cell RCC is managed.
PURPOSE OF REVIEW: As molecular profiling of renal cell carcinoma (RCC) continues to elucidate novel targets for nonclear cell histologies, understanding the landscape of these targets is of utmost importance. In this review, we highlight the genomic landscape of nonclear cell RCC and its implications for current and future systemic therapies. RECENT FINDINGS: Several genomic studies have described the mutational burden among nonclear cell histologies. These studies have highlighted the importance of MET in papillary RCC and led to several clinical trials evaluating the efficacy of MET inhibitors for papillary RCC. The success of immune checkpoint inhibitors, such as ipilimumab and nivolumab, in clear cell RCC has led to ongoing trials evaluating these novel therapeutics in nonclear cell RCC. SUMMARY: Genomic profiling has allowed for the evaluation of novel targets for nonclear cell RCC. This evolving therapeutic landscape is being explored in promising, ongoing trials that have the potential for changing how nonclear cell RCC is managed.
Authors: Yasser Ged; Ying-Bei Chen; Andrea Knezevic; Jozefina Casuscelli; Almedina Redzematovic; Renzo G DiNatale; Maria I Carlo; Chung-Han Lee; Darren R Feldman; Sujata Patil; A Ari Hakimi; Paul Russo; Robert J Motzer; Martin H Voss Journal: Clin Genitourin Cancer Date: 2019-04-01 Impact factor: 2.872
Authors: Nizar M Tannir; Eric Jonasch; Laurence Albiges; Emre Altinmakas; Chaan S Ng; Surena F Matin; Xuemei Wang; Wei Qiao; Zita Dubauskas Lim; Pheroze Tamboli; Priya Rao; Kanishka Sircar; Jose A Karam; David F McDermott; Christopher G Wood; Toni K Choueiri Journal: Eur Urol Date: 2015-11-26 Impact factor: 20.096
Authors: A Ravaud; S Oudard; M De Fromont; C Chevreau; G Gravis; S Zanetta; C Theodore; M Jimenez; E Sevin; B Laguerre; F Rolland; M Ouali; S Culine; B Escudier Journal: Ann Oncol Date: 2015-03-23 Impact factor: 32.976
Authors: Michael S Gordon; Michael Hussey; Raymond B Nagle; Primo N Lara; Philip C Mack; Janice Dutcher; Wolfram Samlowski; Joseph I Clark; David I Quinn; Chong-Xian Pan; David Crawford Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Toni K Choueiri; Ulka Vaishampayan; Jonathan E Rosenberg; Theodore F Logan; Andrea L Harzstark; Ronald M Bukowski; Brian I Rini; Sandy Srinivas; Mark N Stein; Laurel M Adams; Lone H Ottesen; Kevin H Laubscher; Laurie Sherman; David F McDermott; Naomi B Haas; Keith T Flaherty; Robert Ross; Peter Eisenberg; Paul S Meltzer; Maria J Merino; Donald P Bottaro; W Marston Linehan; Ramaprasad Srinivasan Journal: J Clin Oncol Date: 2012-12-03 Impact factor: 44.544
Authors: Nizar M Tannir; Sabina Signoretti; Toni K Choueiri; David F McDermott; Robert J Motzer; Abdallah Flaifel; Jean-Christophe Pignon; Miriam Ficial; Osvaldo Arén Frontera; Saby George; Thomas Powles; Frede Donskov; Michael R Harrison; Philippe Barthélémy; Scott S Tykodi; Judit Kocsis; Alain Ravaud; Jeronimo R Rodriguez-Cid; Sumanta K Pal; Andre M Murad; Yuko Ishii; Shruti Shally Saggi; M Brent McHenry; Brian I Rini Journal: Clin Cancer Res Date: 2020-09-01 Impact factor: 12.531
Authors: Samra Turajlic; Hang Xu; Kevin Litchfield; Andrew Rowan; Stuart Horswell; Tim Chambers; Tim O'Brien; Jose I Lopez; Thomas B K Watkins; David Nicol; Mark Stares; Ben Challacombe; Steve Hazell; Ashish Chandra; Thomas J Mitchell; Lewis Au; Claudia Eichler-Jonsson; Faiz Jabbar; Aspasia Soultati; Simon Chowdhury; Sarah Rudman; Joanna Lynch; Archana Fernando; Gordon Stamp; Emma Nye; Aengus Stewart; Wei Xing; Jonathan C Smith; Mickael Escudero; Adam Huffman; Nik Matthews; Greg Elgar; Ben Phillimore; Marta Costa; Sharmin Begum; Sophia Ward; Max Salm; Stefan Boeing; Rosalie Fisher; Lavinia Spain; Carolina Navas; Eva Grönroos; Sebastijan Hobor; Sarkhara Sharma; Ismaeel Aurangzeb; Sharanpreet Lall; Alexander Polson; Mary Varia; Catherine Horsfield; Nicos Fotiadis; Lisa Pickering; Roland F Schwarz; Bruno Silva; Javier Herrero; Nick M Luscombe; Mariam Jamal-Hanjani; Rachel Rosenthal; Nicolai J Birkbak; Gareth A Wilson; Orsolya Pipek; Dezso Ribli; Marcin Krzystanek; Istvan Csabai; Zoltan Szallasi; Martin Gore; Nicholas McGranahan; Peter Van Loo; Peter Campbell; James Larkin; Charles Swanton Journal: Cell Date: 2018-04-12 Impact factor: 41.582
Authors: Arnav Srivastava; Sai K Doppalapudi; Hiren V Patel; Ramaprasad Srinivasan; Eric A Singer Journal: Curr Opin Oncol Date: 2022-05-01 Impact factor: 3.915